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httpicense.Abstract Background: Thoracic manifestations such as pleural effusion, pneumonia, pulmonary
haemorrhage and haemoptysis have been reported in dengue infection. Dengue haemorrhagic fever
(DHF) can result in acute respiratory distress syndrome. Dengue shock syndrome (DSS) is reported
to be the third leading cause of ARDs in dengue endemic area. So, the aim of our study was to eval-
uate the incidence of pulmonary manifestations among dengue hospitalized cases in the Interna-
tional-Yemen Hospital-Taiz which is an endemic area.
Subjects and methods: This study was conducted in 100 patients seropositive of dengue con-
ﬁrmed by real time-PCR (RT-PCR). Respiratory manifestations were recorded and all clinical
examination ﬁndings were recovered. Baseline investigations including CBC, haematocrit, liver,
renal proﬁle, ABG, dengue virus IgM and IgG and RT-PCR, plain X-ray chest P.A. and lat views
and CT chest were done.
Results: Young age patients and patients with co-morbidity are risky to severe form of dengue
fever and have a high risk of death. As regards co-morbidities, chronic chest disease and cardiac
disease are mostly vulnerable to DHF and DSS. The most presenting respiratory manifestations
were ARDS, pulmonary haemorrhage then pneumonitis and pleural effusion.
Conclusion: Incidence of pulmonary manifestations among cases of DHF and DSS is frequent
and can be used as an indicator of serious presentation of the patients.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.096450083.
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Dengue fever (DF) is the commonest of the arboviral infec-
tions in humans [1]. The global incidence of dengue haemor-
rhagic fever (DHF) has increased dramatically in recent
decades [2]. Also, dengue is a mosquito-borne infection that
in recent years has become a major international public health
problem [3]. Dengue fever (DF) has been known for more than
a century in the tropical areas of South East Asia and the Wes-
tern Paciﬁc regions [4]. Many DF cases are self-limiting but itshe Egyptian Society of Chest Diseases and Tuberculosis.
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Table 1 Demographic data of hospitalized cases with dengue fever as regards age, sex, co-morbidity and the need for mechanical
ventilation.
Demographic data Cured cases Died cases Total P-value
No (45) % No (55) %
Age
650 years 25 55.6 40 72.7 65 0.07
>50 years 20 44.4 15 27.3 35
Sex
Male 25 55.6 29 52.7 54 0.77
Female 20 44.4 26 47.3 46
Co-morbidity
Yes 2 4.4 35 63.6 37 <0.001**
No 43 95.6 20 36.4 63
Need for M.V.
Yes 5 11.1 55 100.0 60 <0.001**
No 40 88.9 0 0.0 40
** Statistically highly signiﬁcant P-value.
Table 2 Clinical presentations of dengue disease among the studied cases.
Clinical presentation Cured cases Died cases Total P-value
No % No %
Dengue fever 43 95.6 0 0.0 43 <0.001**
Dengue haemorrhage fever (DHF) 2 4.4 40 72.7 42 <0.001**
Dengue shock syndrome (DSS) 0 0.0 15 27.3 15 <0.001**
** Statistically highly signiﬁcant P-value.
320 N.A. Mohamed et al.complications like haemorrhage and shock can be life-threat-
ening. If untreated, mortality from the complications of DF
is as high as 20%. The endothelium is the target of the immu-
nopathological mechanisms in dengue and DHF. The hall-
mark is vascular permeability and coagulation disorders.
These mechanisms can explain varied systemic involvement
[5]. Dengue haemorrhagic fever can result in acute respiratory
distress syndrome (ARDS) [6]. Dengue virus antigen is found
in alveolar lining cells of the lung. Increased permeability of
the alveolar-capillary membrane results in oedema in the alve-
oli and interstitial spaces which leads to pulmonary dysfunc-
tion [7]. Dengue shock syndrome is reported to be the third
leading cause of ARDS in the paediatric intensive care in den-
gue endemic area. Pulmonary haemorrhage with or without
haemoptysis has also been reported in DHF [8].
Pleural effusion, ascites can be consistent with increased
vascular permeability, plasma leakage, abnormalities of hae-
mostasis and protein losing shock syndrome which commonly
occur in the pathogenesis [9].
So, the aim of our study is to evaluate the incidence of pul-
monary manifestations among dengue hospitalized cases in the
International-Yemen Hospital-Taiz which is one of the ende-
mic areas.
Subjects and methods
This study was conducted in 100 patients seropositive of den-
gue conﬁrmed by RT-PCR, these patients were admitted to the
International Yemen-Hospital Taiz from August to December
2009, during the outbreak of dengue in Taiz.All studied patients were subjected to:
(1) Full clinical history and physical examination according
to WHO [10] (clinical suspicion of dengue fever on the
basis of the presence of acute febrile illness, myalgia,
headache, retro-orbital pain, bleeding, haemoptysis,
shock, low platelet count, cough, dyspnoea and chest
pain) were registered in the study, informed consent
was obtained from the patients or their relatives.
(2) Baseline investigations, including CBC haematocrit,
liver proﬁle, renal proﬁle and arterial blood gases.
(3) Serological tests including dengue virus IgM and IgG.
(4) Real time RT-PCR for dengue virus.
(5) Chest X-ray P.A. and lat views.
(6) CT-chest without contrast.
All respiratory manifestations in the cases were recorded.
* Serological testing:
Sera were evaluated by IgM antibody capture ELISA
(MACELISA) and indirect IgG ELISA to inactivated
dengue virus produced in tissue culture at the CDC in
San Juan, Puerto Rico [11].
* Real-time RT-PCR detection:The real-time RT-PCR assay for DEN-1 is adapted from
the method of Houng et al. [12]. The assay was optimized
to run as a one-step real time RT-PCR using the super-
script III platinum one-step quantitative RT-PCR system
(Invitrogen, Carlsabd, CA) on an ABF 7500 sequence
detection system instrument (Applied Biosystems).
Table 3 Co-morbidities as regards different dengue presentations, dengue fever, DHF and DSS.
Co-morbidity Dengue fever DHF DSS P-value
No (43) % No (42) % No(15) %
Chronic chest disease 0 0.0 10 23.8 5 33.3 <0.001**
Cardiac disease 0 0.0 7 16.6 2 13.3 0.02*
Renal disease 0 0.0 2 4.8 1 6.6 0.29
Hepatic disease 0 0.0 2 4.8 1 6.6 0.29
Diabetes mellitus 0 0.0 4 9.5 1 6.6 0.67
Total 0 0.0 25 59.5 10 66.6 <0.001**
* Statistically signiﬁcant P-value.
** Statistically highly signiﬁcant P-value.
Table 4 Thoracic presentations as regards dengue fever, DHF and DSS.
Thoracic manifestations Dengue fever DHF DSS P-value
No (43) % No (42) % No(15) %
ARDS 0 0.0 8 19.4 8 53.3 <0.001**
Pulmonary haemorrhage 0 0.0 9 21.4 1 6.6 0.003*
Pneumonitis
Unilat 0 0.0 0 0.0 0 0.0 0.49
Bilat 0 0.0 4 9.5 1 6.6 0.12
Pleural eﬀusion 0 0.0 3 7.14 0 0.0 0.12
Pone presentation 0 0.0 16 38.1 5 33.3 <0.001**
Total 0 0.0 40 95.2 15 100 <0.001**
* Statistically signiﬁcant P-value.
** Statistically highly signiﬁcant P-value.
Table 5 Clinical presentation of patients who developed respiratory affection and those who did not.
Symptoms Dengue cases with resp. complication Dengue cases without resp. complication P-value
No (57) % No (43) %
Fever 57 100.0 43 100.0 1.0
Vomiting 7 12.3 20 46.5 0.01*
Body pain 55 96.5 43 100.0 0.5
Headache 49 89.1 40 93.0 0.34
Retro-orbital pain 35 65.4 18 41.9 0.05*
Drowsiness 5 8.8 29 67.4 <0.001**
Shock 52 91.2 - 0.0 <0.001**
Cough 30 52.6 8 18.6 <0.001**
Haemoptysis 32 56.1 - 0.0 <0.001**
Dyspnoea 57 100.0 - 0.0 <0.001**
Bleeding from other sites 25 43.9 - 0.0 <0.001**
* Statistically signiﬁcant P-value.
** Statistically highly signiﬁcant P-value.
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Data were checked, entered and analysed by using SPSS ver-
sion 19. Data were represented as number and percentage
for categorical variables Chi-squared (v2) or Fisher exact test
was used when appropriate and P< 0.05 was considered sta-
tistically signiﬁcant.Results
Hundred (100) cases of seropositive dengue were admitted to
the International-Yemen Hospital, Taiz, from August toDecember 2009. They were included in our study. On classify-
ing the cases according to the WHO criteria [10], they were 43
cases with dengue fever, 42 cases with DHF and 15 cases with
DSS (Table 2).
Analysis of demographic data in Table 1 clariﬁes that
young age patients with co-morbidity are risky to severe dis-
ease and death. All the died patients were in need for mechan-
ical ventilation.
Table 3 showed that patients with chronic chest disease and
cardiac patients are vulnerable to severe form of dengue fever
like DHF and DSS with high mortality.
Table 4 showed that, ARDS and pulmonary haemorrhage
signiﬁcantly presented among cases of DHF and DDS.
322 N.A. Mohamed et al.Table 5 clariﬁes that, fever, body pain, shock, haemoptysis,
and dyspnoea are markedly presented among dengue fever
cases with respiratory complications.
Table 1 shows there is a highly signiﬁcant difference be-
tween cured and died cases as regards co-morbidity and need
for MV.
There is an increased frequency of died cases of dengue dis-
ease especially in DHF and DSS being 72.7% and 27.3%
respectively, of the whole died patients.
Table 3 shows that chronic chest diseases and cardiac dis-
eases were the most frequent co-morbidity among complicated
dengue fever cases (DHF & DSS).
Table 4 shows that all the cases with thoracic affection oc-
curred in DHF and DSS. None of the thoracic affection oc-
curred in the non complicated cases of dengue fever. The
most frequent thoracic manifestations were ARDS in 16 cases,
pulmonary haemorrhage in 10 patients, pneumonitis in ﬁve
cases and pleural effusion in three patients. 21 patients had
more than one presentation.
Table 5 reveals that the most frequent clinical presentations
in patients who developed respiratory affection were fever in
100%, dyspnoea in 100%, body pain in 96.5%, shock in
91.2%, and headache in 89.1% of patients whereas local chest
symptoms like cough and haemoptysis were detected in 52.6%
and 56.1% of patients only.
Discussion
Dengue is an acute febrile viral disease caused by ﬂavivirus.
It occurs in two forms: DF, a milder form of the disease
and DHF, the most severe form. Dengue has become a ma-
jor International Public Health concern in recent years [9]. It
is now endemic in more than 100 countries and threatens
the health of 40% of the world’s population. It is estimated
that 50 million dengue infections occur each year with
5,000,000 cases of DHF and at least 12,000 deaths annually
[13].
Thoracic manifestations such as pleural effusion, pneumo-
nitis, pulmonary haemorrhage and haemoptysis have been re-
ported in dengue infections [14]. Also, dengue haemorrhagic
fever can result in acute respiratory distress syndrome (ARDS)
[6]. Dengue shock syndrome is reported to be the third leading
cause of ARDS in dengue endemic area [8].
So, the aim of our study was to evaluate the incidence of
pulmonary manifestations among dengue hospitalized cases
in the International-Yemen Hospital-Taiz which is an endemic
area. Table 1 showed that most died patients aged 650 years
(72.7% of died cases).
This result is concomitant with WHO [10] who reported
that an estimated 5,000,000 cases of DHF require hospitaliza-
tion each year, of whom a very large proportion is of young
age. Also, without proper treatment, DHF case-fatality rates
can exceed 20%.
This result can be explained by those young age patients
having a greater risk of severe complications. Also, this table
showed that presentation among died patients is towards male.
Also, patients with co-morbidities, have a marked high death
rate than those without co-morbidities (63.6% of died cases).
These results are concomitant with Sen et al. [6] who told,
dengue can be life-threatening in people with chronic diseases
such as diabetes and asthma.Table 2 showed statistically highly signiﬁcant increase of
mortality among DHF and DSS cases than dengue fever cases.
This result is concomitant with Sameer and Anu [5] who told
DHF is an often fatal disease characterized by haemorrhages
and shock syndrome. This can be explained by the fact that
in severe infection, the virus production inside the body is
greatly increased and many more organs (such as the liver
and the bone marrow) can be affected, and ﬂuid from the
blood stream leaks through the wall of small blood vessels into
body cavities. As a result, less blood circulates in the blood
vessels and the blood pressure becomes so low that it cannot
supply sufﬁcient blood to vital organs. Furthermore, dysfunc-
tion of the bone marrow leads to reduced numbers of platelets,
which are necessary for effective blood clotting, this increases
the risk of bleeding, the other major complication of dengue
fever [15].
Table 3 showed that patients with co-morbidities as,
chronic chest disease and cardiac disease have DHF and
DSS with increased death rate.
This result is concomitant with Thong [15] who told that
dengue can be life-threatening in people with chronic diseases.
Table 4 showed the different thoracic manifestations
among dengue cases which clarify, no respiratory manifesta-
tions among mild dengue fever cases but, they are presented
among DHF and DSS by multiple varieties like ARDS, pul-
monary haemorrhage and haemoptysis, pneumonitis unilate-
ral and bilateral, pleural effusion also, there may be more
than one presentation present that leads to increased risk of
death.
The result is concomitant with Lum et al. [7]; Thong [15]
and Sen et al. [6] who told that dengue haemorrhagic fever
can result in acute respiratory distress syndrome (ARDS).
Dengue virus antigen is found in alveolar lining cells in the
lung. Increased permeability of the alveolar–capillary mem-
brane results in oedema in the alveoli and interstitial spaces
which leads to pulmonary dysfunction [7]. Pulmonary haemor-
rhage with or without haemoptysis has also been reported in
DHF [8].
Also, Venkata and Krishnan [9] reported that of the 56 pa-
tients who underwent the study on ﬁfth to seventh day of fever,
55 had right sided pleural effusion (96.46%), 37 had left sided
pleural effusion (66.07%), these ﬁndings can be explained by
increased vascular permeability, plasma leakage, abnormalities
of haemostasis and protein losing shock syndrome, which
commonly occur in DF pathogenesis.
Table 5 showed a signiﬁcant increase in symptoms of the
milder form of dengue fever; acute febrile disease like, fever,
body pain, headache, drowsiness are manifested in patients
having dengue fever without respiratory complications. But,
serious symptoms like, shock, haemoptysis, breathlessness,
bleeding from other sites are manifested among patients with
dengue fever combined with respiratory complications.
These can be explained by, respiratory complications occur
in severe stages of DHF and DSS when the dengue virus anti-
gen is found in alveolar lining cells of the lung that causes an
increased permeability of the alveolar–capillary membrane and
results in ARDS or as part of bleeding in all body oriﬁces due
to decreased platelet count or as secondary infection in cases of
pneumonitis and lastly in severe disease, plasma leakage results
in haemoconcentration and hypoalbuminaemia. So, pleural
effusions and ascites can be detected [15].
Evaluate the incidence of respiratory manifestations of dengue fever in Taiz-Yemen 323Conclusion
The incidence of pulmonary manifestations is high among the
complicated cases of dengue fever (DHF & DSS) and can be
used as an indicator of serious presentation.
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